112 related articles for article (PubMed ID: 28154322)
1. [Non-canonical Activation of Receptor Tyrosine Kinases in Cancer Progression].
Sakurai H
Yakugaku Zasshi; 2017; 137(2):141-144. PubMed ID: 28154322
[TBL] [Abstract][Full Text] [Related]
2. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
Zhou Y; Sakurai H
Biol Pharm Bull; 2017; 40(10):1616-1624. PubMed ID: 28966234
[TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinases: principles and functions in glioma invasion.
Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada J
Adv Exp Med Biol; 2013; 986():143-70. PubMed ID: 22879068
[TBL] [Abstract][Full Text] [Related]
5. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.
Hsu JL; Hung MC
Cancer Metastasis Rev; 2016 Dec; 35(4):575-588. PubMed ID: 27913999
[TBL] [Abstract][Full Text] [Related]
6. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
7. Adaptive responses to antibody based therapy.
Rodems TS; Iida M; Brand TM; Pearson HE; Orbuch RA; Flanigan BG; Wheeler DL
Semin Cell Dev Biol; 2016 Feb; 50():153-63. PubMed ID: 26808665
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
9. EphA2: A promising therapeutic target in breast cancer.
Zhao P; Jiang D; Huang Y; Chen C
J Genet Genomics; 2021 Apr; 48(4):261-267. PubMed ID: 33962882
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
[TBL] [Abstract][Full Text] [Related]
11. Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion.
Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada JI
Adv Exp Med Biol; 2020; 1202():151-178. PubMed ID: 32034713
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
13. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility.
Larsen AB; Pedersen MW; Stockhausen MT; Grandal MV; van Deurs B; Poulsen HS
Mol Cancer Res; 2007 Mar; 5(3):283-93. PubMed ID: 17374733
[TBL] [Abstract][Full Text] [Related]
14. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
16. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
[TBL] [Abstract][Full Text] [Related]
17. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains.
Gehring MP; Pasquale EB
Cell Signal; 2020 Sep; 73():109668. PubMed ID: 32413552
[TBL] [Abstract][Full Text] [Related]
19. Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.
Refaat A; Aminullah ; Zhou Y; Kawanishi M; Tomaru R; Abdelhamed S; Shin MS; Koizumi K; Yokoyama S; Saiki I; Sakurai H
Biochem Biophys Res Commun; 2015 Mar; 458(4):856-61. PubMed ID: 25701783
[TBL] [Abstract][Full Text] [Related]
20. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
